Johnson & Johnson Moves to Acquire Shockwave Medical, a Top 100 Cardiovascular Innovator

Mar 28, 2024 18:40 CST Updated 18:40

Johnson & Johnson

Medical Device R&D and Manufacturer

Shockwave Medical

Cardiovascular Disease Treatment Device Developer

Source | Medical Device Innovation Network

According to the Wall Street Journal, Johnson & Johnson (NYSE: JNJ) intends to acquire another top 100 cardiovascular giant, Shockwave Medical (NASDAQ: SWAV).

The Wall Street Journal reported: According to informed sources, if the acquisition negotiations are successful, a final agreement could be reached within the next few weeks. Additionally, another potential bidder may also seek to merge with Shockwave Medical, but the source did not disclose the specific name of the other buyer.

As early as last year, media reports mentioned that Johnson & Johnson, Medtronic, and Boston Scientific had all expressed acquisition intentions.

Latest Stock Market Information of SWAV

Image Source: Baidu Stock Express

The report caused SWAV's stock price to rise over 11% during the afternoon trading on March 26, reaching $320.46 per share.

Johnson & Johnson Medical Adds a "Tiger General" to Its "Heart"

As early as 2022, Johnson & Johnson completed the acquisition of Abiomed for $16.6 billion to expand its position in the cardiovascular market segment, thereby strengthening its cardiovascular business.

Especially its star product, the minimally invasive heart pump—Impella, known as the world's smallest heart pump, is used for high-risk percutaneous coronary intervention (PCI) procedures and patients with cardiogenic shock. It aims to provide temporary circulatory support for critically ill cardiovascular patients, such as those with complex coronary artery disease, acute myocardial infarction complicated by cardiogenic shock, and acute decompensated chronic heart failure.

Spark a "Lithotripsy Revolution" in the Cardiovascular Field?

In 2023, Johnson & Johnson mentioned in its communication with the media that the company plans to continue expanding into high-growth markets such as interventional cardiology, robotics, and digital, to consolidate its leading market position.

1. Shockwave Medical——Dual Development in Technology and Revenue

Founded in 2009, Shockwave Medical happens to have a significant impact in the field of interventional cardiology, particularly with its unique technology for treating calcified vascular diseases, known as Intravascular Lithotripsy (IVL). This technology combines the principles of traditional balloon angioplasty and lithotripsy, using sonic wave energy to break up calcified deposits within the vessel wall, thereby improving blood flow and minimizing vascular damage.

Its main advantage lies in its protective effect on surrounding vascular tissues, especially when dealing with coronary artery calcified plaques in heart disease patients. Compared with traditional angioplasty, IVL reduces the risk of vascular injury and complications while breaking up calcified plaques, improving the success rate and safety of the procedure. This technology has currently been approved by the U.S. Food and Drug Administration (FDA) for treating severe calcified coronary artery disease and peripheral artery disease.

Moreover, Shockwave Medical's performance has been exceptionally strong, with its annual revenue reaching $489.7 million in 2023. This achievement caused the company to climb 11 positions in Medical Design & Outsourcing's annual MedTech 100 report, ranking 88th, and its stock price is now 10 times higher than at its initial public offering in 2019.

2. Strong Alliance - The Intersection of Cardiovascular Innovation Technologies

Unlike Shockwave Medical, Johnson & Johnson, through its MedTech division, offers a wide range of cardiovascular products with a stronger focus on high-precision treatments, anatomical restoration, and innovative healing methods. These products cover interventional solutions, orthopedics, surgery, and vision care. Notably, Johnson & Johnson's Biosense Webster division specializes in cardiac electrophysiology, providing advanced 3D mapping, data integration, and innovative technologies for treating arrhythmias.

Despite the different focuses of the two companies on product lines and technological development, both are committed to developing high-tech solutions for cardiovascular treatment. Shockwave Medical's expertise and innovation in intravascular lithotripsy can complement Johnson & Johnson's existing product lines and technologies in the cardiovascular medical device field. This complementarity may enhance Johnson & Johnson's position in the cardiovascular disease treatment market, broadening its technological scope and treatment options.

Johnson & Johnson's New Acquisition Move Reveals Strategic Vision: By acquiring Shockwave Medical, Johnson & Johnson not only strengthens its position in intravascular lithotripsy (IVL) technology but also further solidifies its leadership in the cardiovascular market. However, negotiations are still ongoing, and the final outcome remains uncertain. Industry observers and investors are closely watching how this potential acquisition could reshape the competitive landscape of the cardiovascular medical field. This strategic move by Johnson & Johnson represents not only an expansion of its product portfolio but also a forward-looking layout for the future direction of medical innovation.

Cpharm Medical Device ExchangeGroup

Scan the QR code below to join

Medical Device Agent Transformation Exchange Group

Scan the QR code below to join